Search hospitals > Ontario > LONDON
London Health Sciences Centre - University Hospital
Claim this profileLONDON, Ontario N6A 5A5
Global Leader in Ulcerative Colitis
Global Leader in Crohn's Disease
Conducts research for Colitis
Conducts research for Osteoarthritis
Conducts research for Heart Failure
184 reported clinical trials
10 medical researchers
Summary
London Health Sciences Centre - University Hospital is a medical facility located in LONDON, Ontario. This center is recognized for care of Ulcerative Colitis, Crohn's Disease, Colitis, Osteoarthritis, Heart Failure and other specialties. London Health Sciences Centre - University Hospital is involved with conducting 184 clinical trials across 233 conditions. There are 10 research doctors associated with this hospital, such as Michael Chu, MD, Vipul Jairath, James Howard, MD, and Marko Mrkobrada, MD.Top PIs
Michael Chu, MDLondon Health Sciences Centre4 years of reported clinical research
Studies Coronary Artery Disease
Studies Stroke
17 reported clinical trials
26 drugs studied
Vipul JairathLondon Health Sciences Centre1 year of reported clinical research
Studies Crohn's Disease
Studies Ulcerative Colitis
14 reported clinical trials
14 drugs studied
James Howard, MDLondon Health Sciences Centre7 years of reported clinical research
Studies Osteoarthritis
Studies Hip Osteoarthritis
7 reported clinical trials
16 drugs studied
Marko Mrkobrada, MDLondon Health Sciences Centre - University Hospital5 years of reported clinical research
Studies Atrial Fibrillation
Studies Coronavirus
4 reported clinical trials
9 drugs studied
Clinical Trials running at London Health Sciences Centre - University Hospital
Crohn's Disease
Atrial Fibrillation
Heart Failure
Coronary Artery Disease
Stroke
Spinal Cord Injury
Cervical Spondylosis
Spinal Cord Compression
Primary Biliary Cirrhosis
Atrial Flutter
Risankizumab
for Pediatric Crohn's Disease
Crohn's Disease (CD) is a gastrointestinal disease that can cause chronic diarrhea with or without gross bleeding, abdominal pain, weight loss, and fever. This study will assess the pharmacokinetics, efficacy, and safety of risankizumab in pediatric participants with moderately to severely active CD aged 2 to \< 18 years old who have had intolerance or inadequate response to other therapies. Risankizumab is an approved drug for adults with plaque psoriasis, psoriatic arthritis, and CD and is being developed for the treatment of CD in pediatrics. This study is comprised of 3 cohorts that may participate in 3 substudies (SS). Cohort 1(including Sub-cohort 1A) will enroll participants with ages from 6 to less than 18 years. Cohort 2 will enroll participants with ages from 2 to less than 6 years. Cohort 3 will enroll participants with ages from 2 to less than 18 years. SS1 is an open-label induction period where participants will receive a weight-based induction regimen of risankizumab. SS2 is a double-blind maintenance period where participants will be randomized to receive 1 of 2 doses of weight-based induction regimen of risankizumab. SS3 is an open-label extension period where participants will receive risankizumab based off of their response in SS2. Approximately 118 pediatric participants with CD will be enrolled at around 100 sites worldwide. Participants in SS1 will receive risankizumab intravenously during the 12-week induction period. Participants in SS2 will receive risankizumab subcutaneously during the 52-week randomized maintenance period. Participants in SS3 will receive risankizumab subcutaneously during the 208-week open label period. Participants will be followed-up for approximately 140 days. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Recruiting2 awards Phase 3
Tulisokibart
for Crohn's Disease
The purpose of this protocol is to evaluate the efficacy and safety of tulisokibart in participants with moderately to severely active Crohn's disease. Study 1's primary hypotheses are that at least 1 tulisokibart dose level is superior to placebo in the proportion of participants achieving clinical remission per Crohn's Disease Activity Index score (\<150, US/FDA) or per stool frequency and abdominal pain score (EU/EMA) and in the proportion of participants achieving endoscopic response at Week 52 (US/FDA and EU/EMA), and that at least 1 tulisokibart dose level is superior to placebo in the proportion of participants achieving clinical remission per Crohn's Disease Activity Index score (\<150, US/FDA) or per stool frequency and abdominal pain score (EU/EMA) and in the proportion of participants achieving endoscopic response at Week 12 (US/FDA and EU/EMA). Study 2's primary hypothesis is that at least 1 tulisokibart dose level is superior to placebo in the proportion of participants achieving clinical remission per Crohn's Disease Activity Index score (\<150, US/FDA) or stool frequency and abdominal pain score (EU/EMA) and in the proportion of participants achieving endoscopic response at Week 12 (US/FDA and EU/EMA).
Recruiting1 award Phase 31 criteria
Targeted Therapies
for Crohn's Disease
Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness, swelling), in the digestive tract, most frequently affecting the bowels. It can cause many different symptoms including belly pain, diarrhea, tiredness, and weight loss. Treatments are available but do not work the same for all patients or may stop working over time. This study will evaluate the effectiveness and adverse events of targeted therapies (TaTs) for adult participants with moderate to severe CD. The medicines assessed in this study are risankizumab, ABBV-382 and lutikizumab. When participants join the study, they will be randomized into available study treatment groups. Adult participants with CD will be enrolled. Around 500 participants will be enrolled in the study at approximately 300 sites worldwide. Risankizumab and ABBV-382 are given as an injection under the skin or as an infusion into the vein. Lutikizumab is given as an injection under the skin. Each group includes a 12-week induction period, a 12-week maintenance period, and an optional long-term extension period where medication will be given after the maintenance period. There may be higher treatment burden for participants in this trial compared to their standard of care treatment without participating in this study. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, endoscopies, checking for side effects and completing questionnaires and a daily diary.
Recruiting1 award Phase 21 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at London Health Sciences Centre - University Hospital?
London Health Sciences Centre - University Hospital is a medical facility located in LONDON, Ontario. This center is recognized for care of Ulcerative Colitis, Crohn's Disease, Colitis, Osteoarthritis, Heart Failure and other specialties. London Health Sciences Centre - University Hospital is involved with conducting 184 clinical trials across 233 conditions. There are 10 research doctors associated with this hospital, such as Michael Chu, MD, Vipul Jairath, James Howard, MD, and Marko Mrkobrada, MD.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.